Market news

Weill's acquisition increased his direct holdings to 16,392 shares, valued at $1.4 million at recent market prices, amid a 30% decline in the stock over the past year.

TransMedics is a market-changing player in organ transplant technology, with a unique multi-organ perfusion platform. Read more on TMDX stock here.

Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.

These companies' sell-offs may have gone too far.

Detailed price information for Transmedics Group Inc (TMDX-Q) from The Globe and Mail including charting and trades.

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in two upcoming investor conferences. TransMedics management is scheduled to participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, September 14, 2026, at 3:20 p.m. EST and at the Baird 2026 Global

Detailed price information for Neogenomics Inc (NEO-Q) from The Globe and Mail including charting and trades.

TransMedics Group (NASDAQ:TMDX) outlined its growth strategy at Canaccord Genuity’s 46th Annual Global Growth Conference, highlighting investments in kidney transplantation, European expansion, next-generation technology and broader adoption in heart and lung transplantation. Waleed Hassanein, Tran

Revenue hit $189.9 million with 21% growth as organ transplant volumes surge.

TransMedics stock slipped on mixed results, but its future remains bright.

TMDX's Q2 revenue beat and raised outlook are overshadowed by earnings miss, declining margins and sharply higher operating costs.

TransMedics stock slipped on mixed results, but its future remains bright.

TransMedics Group stock has delivered a 170.9% gain over the past five years, yet the broader valuation checks currently lean toward the shares being undervalued rather than fully priced in. With recent returns mixed over shorter periods, the market seems less certain than the long term chart suggests about what the current price of US$80.75 really reflects. The 170.9% return over five years signals that long term holders in TransMedics Group have already seen substantial value creation,...

TransMedics Group Inc (TMDX) posts 21% revenue growth to $190 million, raises full-year guidance, and advances key clinical programs despite margin pressure from strategic investments.

TransMedics Group (NASDAQ:TMDX) reported record second-quarter revenue as growth in liver procedures, clinical services and transplant logistics offset increased spending on product development, international expansion and infrastructure. Total revenue for the quarter ended June 30 rose 21% year ov

While the top- and bottom-line numbers for TransMedics (TMDX) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

TransMedics (TMDX) delivered earnings and revenue surprises of -12.00% and +3.14%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

TransMedics Group, Inc. previously announced it would report its Q2 2026 results after the market close on August 4, 2026, alongside an earnings call, while also granting stock options and restricted stock units to new employees under Nasdaq Listing Rule 5635(c)(4). UBS’s recent initiation of analyst coverage, combined with new equity awards aimed at retaining and attracting talent, highlights growing institutional attention to TransMedics’ transplant-focused technology platform and...

TransMedics Group (TMDX) heads into a busy early August, with Q2 2026 results and an earnings call scheduled for August 4 after the market close, drawing fresh attention to the stock. See our latest analysis for TransMedics Group. Recent trading in TransMedics Group reflects this renewed attention, with a 1 day share price return of 6.6% and a 30 day share price return of 18.4%, even as the year to date share price return is down 33.5% and the 1 year total shareholder return is down 35.1%...

TransMedics Group (TMDX) has an average rating of overweight and mean price target of $112.89, accor

TransMedics (TMDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart and liver failure, today announced that it will release financial results for the second quarter 2026 after market close on Tuesday, August 4, 2026. The TransMedics management team will host a corresponding conference call beginning at 4:30 p.m. ET / 1:30 p.m. PT.

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. TransMedics Group, Inc. (NASDAQ:TMDX) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI analyst Daniel Markowitz reduced the price target on TMDX to $90 from $100 while maintaining an Outperform rating on […]

TMDX's PAD Aviation investment expands its OCS model into Europe, aiming to boost organ logistics, utilization and adoption.

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the closing of its strategic investment in PAD Aviation, a premier Germany-based private aviation operator.